The phosphorylation, or activation state of kinase-driven signal networks embodies information concerning disease pathogenesis and the ongoing state of kinase associated therapeutic targets. Profiling the tumor phosphoproteome using human tumor biopsy specimens is a crucial component of the perceived upcoming revolution of individualized cancer therapy. A critical unmet need addressed by this application is tissue phosphoprotein stability data, standardized protocols, and novel technologies which can be used in the real world clinical setting (e.g. operating room, outpatient clinic biopsy, radiological suite needle aspiration) for seamless collection, immediate preservation, and real time stability monitoring of phosphoproteins. Our multidisciplinary team has previously developed Laser Capture Microdissection (LCM) and reverse phase protein microarray (RPA) technologies to conduct phosphoproteomic analysis of the tissue microenvironment. We will standardize the RPA technology to simultaneously measure at least 100 known phosphoprotein endpoints with high precision and sensitivity in a human core needle biopsy or fine needle aspirate. This technology will be used to collect previously unknown quantitative information about the tissue half-life of phosphoproteins representing a wide range of signaling pathways, cellular compartments and phosphorylated residues over time zero to 48 hours. These data will become the basis to identify a subset of highly representative and most-labile endogenous phosphoproteins which can be employed as novel surrogate quantitative markers of tissue preservation and phosphoprotein stability. We will employ this stability data and novel surrogate endpoints technology to propose definitive quantitative guidelines for tissue perishability limits. We will create exogenous phosphoprotein sentinel nanoparticles to record the processing history of the specimen for ongoing Quality Assurance. The RPA, surrogate markers, and sentinel technology will be used to rank candidate preservative solutions that stabilize kinases, phosphatases, and phosphoproteins for 24-48 hr at room temperature. The desired outcome will be a complete standardized technology kit which can be employed for routine clinical collection, shipping, early warning of perished tissue, and real time monitoring of tissue phosphoproteins for molecular profiling. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA125698-01A1
Application #
7291263
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (O2))
Program Officer
Rubinstein, Yaffa
Project Start
2008-06-05
Project End
2010-05-31
Budget Start
2008-06-05
Budget End
2009-05-31
Support Year
1
Fiscal Year
2008
Total Cost
$179,404
Indirect Cost
Name
George Mason University
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
077817450
City
Fairfax
State
VA
Country
United States
Zip Code
22030
Staunton, Lisa; Tonry, Claire; Lis, Rosina et al. (2017) Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment. Mol Cancer Res 15:281-293
Spreafico, Filippo; Bongarzone, Italia; Pizzamiglio, Sara et al. (2017) Proteomic analysis of cerebrospinal fluid from children with central nervous system tumors identifies candidate proteins relating to tumor metastatic spread. Oncotarget 8:46177-46190
Federici, Giulia; Gao, Xi; Slawek, Janusz et al. (2013) Systems analysis of the NCI-60 cancer cell lines by alignment of protein pathway activation modules with ""-OMIC"" data fields and therapeutic response signatures. Mol Cancer Res 11:676-85
Golubeva, Yelena; Salcedo, Rosalba; Mueller, Claudius et al. (2013) Laser capture microdissection for protein and NanoString RNA analysis. Methods Mol Biol 931:213-57
Chiechi, Antonella; Mueller, Claudius; Boehm, Kevin M et al. (2012) Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples. Biotechniques 0:1-7
Liotta, Lance A; Petricoin 3rd, Emanuel F (2012) -Omics and cancer biomarkers: link to the biological truth or bear the consequences. Cancer Epidemiol Biomarkers Prev 21:1229-35
Tidwell, J Lille; Liotta, Lance A (2012) Inventions and patents: a practical tutorial. Methods Mol Biol 823:391-408
Zhou, Weidong; Capello, Michela; Fredolini, Claudia et al. (2012) Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J Proteome Res 11:554-63
Mammano, Enzo; Galdi, Francesca; Pierobon, Mariaelena et al. (2012) Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment. Clin Colorectal Cancer 11:268-74
Mueller, Claudius; Edmiston, Kirsten H; Carpenter, Calvin et al. (2011) One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One 6:e23780

Showing the most recent 10 out of 19 publications